B
Bull
Bull · 25%NLSP
$2.96
Scenario price
$7.620
+0.226 (+2.97%)At close
Loading chart…
- High
- 8.300
- Open
- 7.701
- VWAP
- 7.84
- Vol
- 4.76M
- Mkt Cap
- 10.41M
- Low
- 7.600
- Amount
- 37.34M
- EV/EBITDA, TTM
- 0.00
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Valuation Metrics
The current forward P/E ratio for NLS Pharmaceutics AG (NLSP) is -0.09, compared to its 5-year average forward P/E of -2.97.
Alphio AI Price Scenarios for NLSP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NLSP
Events Timeline
News
3.510-30PRnewswireNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
8.510-29NewsfilterNLS Pharmaceutics and Kadimastem Confirm Fulfillment of Key Conditions for Merger and Set Delisting Date for Kadimastem Shares
8.510-29PRnewswireNLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
8.510-27PRnewswireNLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
8.510-23PRnewswireNLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
NLSP FAQ — answered by Alphio AI
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.